5-硝基萘-1-甲酸 | 1975-44-6

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 5-硝基萘-1-甲酸
• 中文别名: 5-硝基萘-1-羧酸
• 英文名称: 5-nitro-1-naphthoic acid
• 英文别名: 5-nitronaphthalene-1-carboxylic acid；5-Nitro-[1]naphthoesaeure；5-Nitro-[1]naphthoesaeure; Brucin-Salz；5-nitro-1-naphthalenecarboxylic acid
• CAS: 1975-44-6
• 化学式: C₁₁H₇NO₄
• mdl: MFCD00093002
• 分子量: 217.181
• InChiKey: XOUKDQBDXPQJJI-UHFFFAOYSA-N

物化性质

• 熔点：
  241.5°C
• 沸点：
  357.72°C (rough estimate)
• 密度：
  1.3654 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2916399090

制备方法与用途

5-硝基萘-1-甲酸是一种用于医药生产的中间体，可通过将α-萘甲酸用发烟硝酸进行硝化反应来制备。

反应信息

• 作为反应物：
  描述：

  5-硝基萘-1-甲酸 在 硝酸 作用下， 生成 4,5-dinitro-[1]naphthoic acid
  参考文献：
  名称：

  Ekstrand, Journal fur praktische Chemie (Leipzig 1954), 1888, vol. <2> 38, p. 247

  摘要：

  DOI：
• 作为产物：
  描述：

  1-萘甲酸 在 X-NO₂ 作用下， 生成 5-硝基萘-1-甲酸
  参考文献：
  名称：

  用于癌症化学治疗研究的新型多胺衍生物的合成

  摘要：

  制备了精胺和亚精胺的选定同系物，类似物和酰化衍生物，以及几种含有酚醛二胺侧链的杂环和芳族化合物，并进行了生物学评估。几种化合物具有对抗B-16黑色素瘤和人鼻咽表皮样癌的活性。

  DOI：

  10.1002/jps.2600700835

文献信息

• [EN] THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD<br/>[FR] COMPOSES THERAPEUTIQUES DANS LESQUELS LA PYRIDINE EST UTILISEE COMME SQUELETTE
  申请人：ASTRAZENECA AB

  公开号：WO2005115986A1

  公开（公告）日：2005-12-08

  Compounds of formulas I, IA, and IB or IC or pharmaceutically acceptable salts thereof: wherein A, A1, A2, A3, A4, R2, R3, R4 and n are as defined in the specifications well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  其中A、A1、A2、A3、A4、R2、R3、R4和n的化合物的公式I、IA和IB或IC或其药学上可接受的盐：其中A、A1、A2、A3、A4、R2、R3、R4和n的定义如规范中所述，以及包括这些化合物的盐和药物组合物已经准备好。它们在治疗中很有用，特别是在疼痛管理中。
• MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME
  申请人：Barany Francis

  公开号：US20140194383A1

  公开（公告）日：2014-07-10

  Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.

  本发明描述了在水中介质中与一个、两个、三个或更多其他单体接触时能够形成具有生物学用途的多聚体的单体。在一方面，这样的单体可能能够在水介质中（例如，体内）与另一个单体结合形成多聚体（例如，二聚体）。考虑的单体可能包括一个配体部分、一个连接元素和一个连接器元素，连接器元素连接配体部分和连接元素。在水介质中，这样的考虑单体可能通过每个连接元素相互连接，因此可能能够实质上同时调节一个或多个生物分子，例如，调节蛋白质上的两个或多个结合域，或者调节不同蛋白质上的结合域。
• Dosing form for reagents, use of said dosing form in organic chemical synthesis and production of said dosing form
  申请人：H. Lundbeck A/S

  公开号：US20030138376A1

  公开（公告）日：2003-07-24

  A dosing form for at least one solid reagent for use in conventional organic and inorganic synthesis, in parallel synthesis, and in split and mix synthesis in combinatorial chemistry is provided as compressed tablets each containing the same predetermined amount of said at least one reagent embedded in a polymer matrix comprising beads of a polymer insoluble in the solvents for the intended synthesis, which tablets are capable of disintegrating in said solvent for release of the at least one reagent and disperse the matrix as polymer beads into the solvent. The polymer beads forming the matrix and the reagents of the dosing form can easily be removed by filtration in order to separate these from a formed soluble product. In a method for producing the dosing form, beads of one or more polymers are mixed with the reagents and compressed into tablets after pre-treatment with an aprotic organic solvent.

  提供了一种用于传统有机和无机合成、并行合成以及在组合化学中的分割和混合合成中使用的至少一种固体试剂的剂型，其为每个压缩片剂，每个压缩片剂包含相同预定量的至少一种试剂，嵌入在聚合物基质中，该聚合物基质包括不溶于预定合成溶剂的聚合物珠，这些片剂能够在所述溶剂中解体以释放至少一种试剂，并将基质分散为聚合物珠进入溶剂中。剂型的聚合物珠形成基质和试剂可以通过过滤轻松地从形成的可溶产品中分离出来。 在生产该剂型的方法中，将一种或多种聚合物的珠与试剂混合，并在用无水有机溶剂预处理后压缩成片剂。
• COFLUORONS AND METHODS OF MAKING AND USING THEM
  申请人：Barany Francis

  公开号：US20140161729A1

  公开（公告）日：2014-06-12

  The present invention is directed to method of using a collection of monomers capable of forming multimers as a fluorescence reporter in different applications such as ligand detection/screening, disease diagnosis, drug discovery or screening, fluorescent labeling and imaging, or other fluorescent methodologies. Each monomer in the collection includes one or more ligand elements useful for binding to a target molecule with a dissociation constant of less than 300 μM and a linker element connected to the ligand elements directly or indirectly through a connector. Association of linker elements of different combinations of monomers, with their ligand elements bound to the target molecule to form a multimer, will generate a unique fluorescent signature different from that produced by those monomers either alone or in association with each other in the absence of the target molecule, when subjected to electromagnetic excitement.

  本发明涉及使用一组能够形成多聚体的单体作为荧光报告物在不同应用中的方法，例如配体检测/筛选、疾病诊断、药物发现或筛选、荧光标记和成像，或其他荧光方法学。该组合中的每个单体均包括一个或多个配体元素，用于与解离常数小于300μM的靶分子结合，并且连接到配体元素的连接器通过直接或间接连接到配体元素。不同单体组合的连接器元素与其配体元素结合到靶分子形成多聚体，将产生一种独特的荧光特征，与那些单体单独或在没有靶分子的情况下相互结合时产生的荧光特征不同，当受到电磁激发时。
• Synthesis and structure-activity study of protease inhibitors. II. Amino- and guanidino-substituted naphthoates and tetrahydronaphthoates.
  作者：TOYOO NAKAYAMA、TOSHIYUKI OKUTOME、RYOJI MATSUI、MASATERU KURUMI、YOJIRO SAKURAI、TAKUO AOYAMA、SETSURO FUJII

  DOI：10.1248/cpb.32.3968

  日期：——

  Various amino-and guanidino-substituted naphthoates and tetrahydronaphthoates were synthesized and evaluated for inhibitory activities against trypsin, plasmin, kallikrein, thrombin and Cl esterase. Among these compounds, phenyl 4-guanidino-1-naphthoate (IIIj) and phenyl 6-guanidino-1-naphthoate (IIIl) exhibited potent and selective trypsin inhibition (IC50 : 4×10-7 and 5×10-8 M, respectively) and phenyl 7-guanidino-1, 2, 3, 4-tetrahydro-1-naphthoate (Vb) and p-ethoxycarbonylphenyl 7-guanidino-1, 2, 3, 4-tetrahydro-1-naphthoate (Vg) had selective inhibitory activities against thrombin (IC50 : 4×10-5 and 1×10-5 M, respectively).

  合成了多种氨基和氨基脲取代的萘酸酯和四氢萘酸酯，并评估了它们对胰蛋白酶、纤溶酶、激肽酶、凝血酶和C1酯酶的抑制活性。在这些化合物中，苯基4-氨基脲-1-萘酸酯（IIIj）和苯基6-氨基脲-1-萘酸酯（IIIl）表现出强效选择性的胰蛋白酶抑制（IC50：4×10^-7和5×10^-8 M，分别），而苯基7-氨基脲-1, 2, 3, 4-四氢-1-萘酸酯（Vb）和对乙氧基羧基苯基7-氨基脲-1, 2, 3, 4-四氢-1-萘酸酯（Vg）则对凝血酶具有选择性抑制活性（IC50：4×10^-5和1×10^-5 M，分别）。